Thomas J. Herzog
#148,347
Most Influential Person Now
Thomas J. Herzog's AcademicInfluence.com Rankings
Thomas J. Herzogphilosophy Degrees
Philosophy
#8079
World Rank
#11393
Historical Rank
Logic
#5112
World Rank
#6476
Historical Rank
Download Badge
Philosophy
Why Is Thomas J. Herzog Influential?
(Suggest an Edit or Addition)Thomas J. Herzog's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States (2013) (558)
- Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. (2013) (462)
- Latest research and treatment of advanced-stage epithelial ovarian cancer (2013) (458)
- Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. (2017) (387)
- Endometrial cancer: a review and current management strategies: part I. (2014) (328)
- Incorporation of pazopanib in maintenance therapy of ovarian cancer. (2014) (304)
- Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. (2010) (298)
- Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. (2007) (257)
- Contemporary management of endometrial cancer (2012) (250)
- Endometrial cancer: a review and current management strategies: part II. (2014) (244)
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. (2014) (236)
- Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers (2003) (234)
- Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. (2015) (232)
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. (2019) (232)
- Prognostic significance of adenocarcinoma histology in women with cervical cancer. (2012) (209)
- Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. (1995) (206)
- Recurrent Ovarian Cancer (2004) (180)
- Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. (2019) (179)
- Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. (2012) (173)
- Preoperative lymph node staging of early‐stage cervical carcinoma by [18F]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography (2005) (169)
- Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. (2004) (169)
- Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. (2002) (161)
- SGO White Paper on ovarian cancer: etiology, screening and surveillance. (2010) (158)
- Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (1997) (152)
- Prognostic factors for high‐risk early‐stage epithelial ovarian cancer (2008) (147)
- Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. (2003) (143)
- The utility of preoperative endometrial sampling for the detection of uterine sarcomas. (2008) (131)
- Mutational analysis of MLH1 and MSH2 in 25 prospectively‐acquired RER+ endometrial cancers (1997) (128)
- Fertility preservation in young women with epithelial ovarian cancer (2009) (126)
- Morbidity and Mortality of Peripartum Hysterectomy (2010) (125)
- Clinical significance of microsatellite instability in endometrial carcinoma (2000) (121)
- Endometriosis: where are we and where are we going? (2016) (120)
- Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. (2012) (119)
- Effect of Surgical Volume on Outcomes for Laparoscopic Hysterectomy for Benign Indications (2012) (117)
- Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer (2010) (116)
- The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. (2010) (116)
- Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. (2000) (115)
- Use of complementary and alternative medicine among women with gynecologic cancers. (2002) (113)
- Ovarian cancer: a focus on management of recurrent disease (2006) (109)
- Regionalization of Care for Obstetric Hemorrhage and Its Effect on Maternal Mortality (2010) (108)
- Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers: Evidence for Distinct Tumor Behavior (2008) (106)
- Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. (2003) (103)
- The impact of cervical cancer on quality of life--the components and means for management. (2007) (100)
- FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. (2002) (99)
- Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. (2013) (97)
- Racial disparities for uterine corpus tumors (2009) (96)
- Natural history and outcome of mucinous carcinoma of the ovary. (2011) (94)
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. (2016) (94)
- Predictors of massive blood loss in women with placenta accreta. (2011) (93)
- The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. (2008) (91)
- Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. (2012) (90)
- The Effect of Surgeon Volume on Outcomes and Resource Use for Vaginal Hysterectomy (2010) (89)
- Natural history of established low grade cervical intraepithelial (CIN 1) lesions. (2008) (89)
- Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. (2009) (87)
- Patterns of care and treatment outcomes for elderly women with cervical cancer (2012) (87)
- ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? (2010) (87)
- Effect of Radical Cytoreductive Surgery on Omission and Delay of Chemotherapy for Advanced-Stage Ovarian Cancer (2012) (85)
- An Economic Analysis of Robotically Assisted Hysterectomy (2014) (84)
- Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. (2003) (84)
- Failure to rescue as a source of variation in hospital mortality for ovarian cancer. (2012) (84)
- Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. (2012) (82)
- A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. (2007) (82)
- Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. (2003) (81)
- Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. (2016) (81)
- Progression‐free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay (2004) (80)
- A meta‐analysis of the efficacy of intraperitoneal cisplatin for the front‐line treatment of ovarian cancer (2007) (80)
- A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. (2013) (79)
- Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer (2014) (77)
- Long-term outcome and natural history of uterine adenosarcomas. (2010) (77)
- Defining the limits of radical cytoreductive surgery for ovarian cancer. (2011) (74)
- Initial lessons learned in HPV vaccination. (2008) (73)
- Epithelial Ovarian Tumors of Low Malignant Potential: The Role of Microinvasion (2002) (73)
- Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. (2004) (71)
- Scientific Evidence Underlying the American College of Obstetricians and Gynecologists' Practice Bulletins (2011) (70)
- Trends in Surgical Mesh Use for Pelvic Organ Prolapse From 2000 to 2010 (2012) (68)
- Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. (2014) (68)
- Resource utilization for ovarian cancer patients at the end of life: how much is too much? (2005) (65)
- A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. (2006) (65)
- Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma (2010) (63)
- Cervical carcinoma in the elderly (2005) (63)
- Fertility-Conserving Surgery for Young Women With Stage IA1 Cervical Cancer: Safety and Access (2010) (62)
- The current treatment of recurrent ovarian cancer (2006) (62)
- Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. (2008) (61)
- Paclitaxel poliglumex for ovarian cancer (2011) (61)
- Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. (2010) (60)
- Ribosomal DNA methylation in patients with endometrial carcinoma (2002) (60)
- Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. (2001) (59)
- Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. (2011) (59)
- The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. (2012) (59)
- Risk and Predictors of Malignancy in Women with Endometrial Polyps (2011) (57)
- Venous Thromboembolism and Use of Prophylaxis Among Women Undergoing Laparoscopic Hysterectomy (2011) (57)
- A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? (2004) (57)
- Safety of ovarian preservation in premenopausal women with endometrial cancer. (2009) (57)
- Successful in vitro fertilization pregnancy after conservative management of endometrial cancer. (2001) (56)
- Update on the role of topotecan in the treatment of recurrent ovarian cancer. (2002) (56)
- Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. (2011) (56)
- Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. (2009) (56)
- Therapeutic role of lymphadenectomy for cervical cancer (2011) (55)
- A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. (2018) (55)
- Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. (2013) (54)
- Influence of Surgical Volume on Outcome for Laparoscopic Hysterectomy for Endometrial Cancer (2012) (54)
- Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability (1999) (54)
- Synchronous ovarian metastases at the time of laparotomy for colon cancer. (2004) (53)
- Age considerations when vaccinating against HPV. (2008) (53)
- Increased Risk for Hereditary Nonpolyposis Colorectal Cancer-Associated Synchronous and Metachronous Malignancies in Patients with Microsatellite Instability-Positive Endometrial Carcinoma Lacking MLH1 Promoter Methylation (2004) (53)
- Effect of Surgical Volume on Morbidity and Mortality of Abdominal Hysterectomy for Endometrial Cancer (2011) (52)
- The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. (2011) (50)
- A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. (2013) (50)
- Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. (2010) (50)
- Patterns of use of hemostatic agents in patients undergoing major surgery. (2014) (50)
- Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. (2009) (50)
- Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. (2017) (50)
- Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta (2013) (49)
- The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer (2007) (49)
- Contemporary Clinical Management of Endometrial Cancer (2013) (48)
- Improved survival for fallopian tube cancer (2008) (48)
- A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients (2019) (47)
- Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. (2020) (47)
- Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. (2006) (46)
- BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. (2016) (46)
- Sarcoma of the cervix: natural history and outcomes. (2010) (45)
- Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? (2004) (45)
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial (2014) (45)
- Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. (2019) (44)
- Current management of patients with invasive cervical carcinoma. (2001) (44)
- Reducing the burden of glandular carcinomas of the uterine cervix. (2007) (43)
- MSI in endometrial carcinoma: Absence of MLH1 promoter methylation is associated with increased familial risk for cancers (2002) (43)
- A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213) (2015) (43)
- Morbidity and mortality of surgery for endometrial cancer in the oldest old. (2011) (42)
- The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. (2004) (42)
- Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. (2013) (41)
- Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. (2005) (40)
- PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy (2015) (39)
- Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. (2004) (39)
- Access to Conservative Surgical Therapy for Adolescents With Benign Ovarian Masses (2012) (39)
- Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma (2008) (38)
- New approaches for the management of cervical cancer. (2003) (38)
- Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. (2011) (38)
- Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. (2002) (37)
- Morbidity of cytoreductive surgery in the elderly. (2004) (37)
- Microinvasive adenocarcinoma of the cervix. (2012) (37)
- Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. (2000) (36)
- Variation in Ovarian Conservation in Women Undergoing Hysterectomy for Benign Indications (2013) (36)
- Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? (2004) (36)
- Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis. (2014) (36)
- Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. (2012) (36)
- Use of Guideline-Based Antibiotic Prophylaxis in Women Undergoing Gynecologic Surgery (2013) (36)
- CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. (2007) (35)
- Surgical and systemic management of endometrial cancer: an international survey (2015) (34)
- Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. (1999) (34)
- New Innovations in Cervical Cancer Screening (2001) (34)
- FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. (2017) (33)
- Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy (2002) (33)
- The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. (2008) (32)
- Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter (2002) (31)
- Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. (2016) (31)
- Investigational agents in development for the treatment of ovarian cancer (2013) (31)
- Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. (2002) (31)
- Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. (2005) (30)
- Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. (1998) (30)
- Meigs' Syndrome With an Elevated CA 125 From Benign Brenner Tumors (2001) (30)
- Medically inoperable stage I endometrial carcinoma: a few dilemmas in radiotherapeutic management. (1996) (30)
- Quality of Venous Thromboembolism Prophylaxis in Patients Undergoing Oncologic Surgery (2011) (30)
- Gestational trophoblastic diseases: new standards for therapy (2000) (29)
- Emerging therapies: angiogenesis inhibitors for ovarian cancer (2015) (29)
- Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. (2007) (28)
- Adherence to Evidence-Based Guidelines for Preoperative Testing in Women Undergoing Gynecologic Surgery (2010) (28)
- Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. (2001) (28)
- The role of Notch and gamma-secretase inhibition in an ovarian cancer model. (2013) (28)
- Acceptance and Compliance With Postpartum Human Papillomavirus Vaccination (2012) (28)
- Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. (2005) (27)
- Potential of cervical electrosurgical excision procedure for diagnosis and treatment of cervical intraepithelial neoplasia. (1995) (27)
- Failure to rescue after major gynecologic surgery. (2013) (27)
- Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. (2010) (27)
- Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery. (1999) (27)
- The impact of cervical cancer on quality of life: a personal account. (2008) (27)
- Correlates of length of stay in gynecologic oncology patients undergoing inpatient surgery. (1993) (27)
- Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. (2005) (26)
- Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer: A Phase II Study (2014) (26)
- Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? (2017) (26)
- COVID‐19 pandemic and impact on cancer clinical trials: An academic medical center perspective (2020) (26)
- Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. (2015) (26)
- Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. (2016) (26)
- Overview of a chemoresponse assay in ovarian cancer (2014) (25)
- Low frequency of CDKN2 mutation in endometrial carcinomas (1995) (25)
- Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. (2004) (25)
- Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. (2007) (25)
- Impact of molecular profiling on overall survival of patients with advanced ovarian cancer (2016) (25)
- Analysis of MSH3 in Endometrial Cancers With Defective DNA Mismatch Repair (1998) (25)
- Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines (1994) (25)
- Recurrent vulvar carcinoma in pregnancy. (2004) (24)
- Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. (1996) (24)
- Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy (2017) (24)
- Morbidity of Cytoreductive Surgery in the Elderly (2003) (24)
- The clinical implications of hydronephrosis and the level of ureteral obstruction in stage IIIB cervical cancer. (1998) (24)
- Long-term semi-permanent catheter use for the palliation of malignant ascites. (2006) (23)
- Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. (2018) (23)
- Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. (2018) (23)
- Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. (2004) (22)
- Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. (2011) (22)
- Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer. (2013) (22)
- Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. (2016) (21)
- The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. (2007) (21)
- What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? (2010) (21)
- CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. (2006) (20)
- A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. (2014) (20)
- SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. (2014) (20)
- Pharmacotherapy of endometrial cancer (2009) (20)
- A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). (2011) (19)
- Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. (2011) (19)
- Stage IIIA Endometrial Carcinoma: Outcome and Predictors of Survival (2009) (19)
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer (2021) (18)
- Clinical experience with topotecan in relapsed ovarian cancer. (2003) (18)
- Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. (2013) (18)
- Interferon-γ and Tumor Necrosis Factor-α Induce Synergistic Cytolytic Effects in Ovarian Cancer Cell Lines—Roles of the TR60 and TR80 Tumor Necrosis Factor Receptors☆ (1999) (18)
- OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. (2019) (18)
- The role of maintenance therapy and novel taxanes in ovarian cancer. (2006) (18)
- Utility and Cost‐Effectiveness of Preoperative Autologous Blood Donation in Gynecologic and Gynecologic Oncology Patients (2002) (18)
- Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal? (2013) (18)
- Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur (2001) (18)
- A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. (2020) (17)
- Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study. (2011) (17)
- Quality of Perioperative Venous Thromboembolism Prophylaxis in Gynecologic Surgery (2011) (17)
- The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. (2016) (16)
- Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells. (2010) (16)
- Cancer Among First‐degree Relatives of Probands With Invasive and Borderline Ovarian Cancer (1998) (16)
- Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. (2021) (16)
- A review of the current evidence for maintenance therapy in ovarian cancer. (2009) (16)
- The efficacy of trabectedin in treating ovarian cancer (2017) (16)
- Trends in Hospital Volume and Patterns of Referral for Women With Gynecologic Cancers (2013) (15)
- PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. (2011) (15)
- Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. (2019) (15)
- Advancing Drug Development in Gynecologic Malignancies (2019) (15)
- How does public policy impact cervical screening and vaccination strategies? (2010) (15)
- Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. (2018) (15)
- Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. (2003) (14)
- Human papillomavirus: emerging trends in detection and management. (2002) (14)
- Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. (2010) (14)
- Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability. (1999) (14)
- Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. (2006) (14)
- Current treatment strategies for endometrial cancer (2008) (14)
- Molecular variations in uterine carcinosarcomas identify therapeutic opportunities (2020) (13)
- Radical Hysterectomy for Cervical Cancer in Obese Women (2000) (13)
- Leptomeningeal carcinomatosis from ovarian cancer (2012) (13)
- Placental Site Trophoblastic Tumor Presenting With a Pneumothorax During Pregnancy (2002) (13)
- Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies (2003) (13)
- Prognostic Significance of Mucinous Differentiation of Endometrioid Adenocarcinoma of the Endometrium (2013) (13)
- Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis (2019) (13)
- Clinical applications of immunohistochemistry in gynecological malignancies (2006) (12)
- The role of tumor necrosis factor receptors in tumor necrosis factor-α - mediated cytolysis of ovarian cancer cell lines☆☆☆★ (1996) (12)
- Patterns of care for locally advanced vulvar cancer. (2013) (12)
- Utilization and Safety of Sodium Hyaluronate-Carboxymethylcellulose Adhesion Barrier (2013) (12)
- Workshop: options for therapy in ovarian cancer. (2003) (12)
- Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study (2013) (12)
- Latest research and clinical treatment of advanced-stage epithelial ovarian cancer (2013) (12)
- What is the clinical value of adding tamoxifen to progestins in the treament of advanced or recurrent endometrial cancer (2004) (12)
- Assessing the adequacy of surgical staging for ovarian cancer. (2006) (11)
- The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin (1993) (11)
- A 1-Mb bacterial clone contig spanning the endometrial cancer deletion region at 1p32-p33. (1999) (11)
- The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. (2002) (11)
- NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype. (2013) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. (2002) (10)
- Carboplatin—gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration (2010) (10)
- Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. (2015) (10)
- Evidence for a Protein Synthesis-Dependent and -Independent TNFα Cytolytic Mechanism (1995) (9)
- Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. (2014) (9)
- Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? (2018) (9)
- 15th Biennial Meeting of the International Gynecologic Cancer Society (2014) (9)
- Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors. (1999) (9)
- COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies (2020) (9)
- 3Geriatric assessment and tolerance to chemotherapy in elderly women with ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group study (2014) (8)
- Relationship of ovarian neoplasms and body mass index. (2005) (8)
- AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results. (2018) (8)
- The new era of cervical cancer prevention: HPV vaccination. (2008) (8)
- Targeted Therapies in Epithelial Ovarian Cancer (2010) (8)
- Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial (2016) (8)
- The Impact of Opportunistic Salpingectomy on Ovarian Cancer Mortality and Healthcare Costs: A Call For Universal Insurance Coverage. (2021) (7)
- Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma. (2001) (7)
- Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. (2016) (7)
- Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer (2021) (7)
- Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes. (2000) (7)
- The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: Hope or Hoax? (2012) (7)
- Loss of heterozygosity of chromosome 3p sequences is an infrequent event in endometrial cancer. (1996) (7)
- Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. (2021) (7)
- The current status of secondary cytoreduction in ovarian cancer: a systematic review. (2020) (7)
- Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. (2020) (7)
- A preoperative and intraoperative scoring system to predict nodal metastasis in endometrial cancer (2017) (7)
- Comparison of the cytostatic and cytolytic activity of tumor necrosis factor-α and interleukin 1α in human malignant cell lines (1992) (6)
- What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? (2004) (6)
- Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer (2019) (6)
- Role of pelvic and paraaortic lymphadenectomy (2014) (6)
- Growth modulatory effects of granulocyte-macrophage colony-stimulating factor on human cell lines derived from gynecologic malignancies. (1996) (6)
- Joint ENGOT and GOG Foundation requirements for trials with industry partners (2019) (6)
- Effects of radiation on TNFα-mediated cytolysis of cell lines derived from cervical carcinomas (1992) (6)
- Safety of conservative management of ovarian masses during pregnancy. (2013) (6)
- Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. (2015) (6)
- Cytoreductive surgery: abdominal retroperitoneum and adenopathy (2005) (6)
- Unintended Consequences: Surgical Complications in Gynecologic Cancer (2013) (5)
- RECURRENT OVARIAN TUMOR WITH LOW MALIGNANT POTENTIAL AND CARDIAC METASTASIS (1997) (5)
- Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. (2008) (5)
- PD-1 and PD-L1 expression in 1599 gynecological malignancies - implications for (2014) (5)
- Randomized comparison of laparoscopic and open lymphadenectomy in pigs. (1999) (5)
- The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin. (1992) (5)
- Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers. (2021) (5)
- Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer (2021) (5)
- A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. (2020) (5)
- Utility of cell salvage in women undergoing abdominal myomectomy. (2014) (5)
- Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemo (2015) (4)
- A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers. (2018) (4)
- Corrigendum to “Endometrial cancer: A review and current management strategies: Part I” [Gynecol Oncol 134 (2014) 385–392] (2014) (4)
- A comparison of dosimetric parameters in PET-based active bone marrow volume and total bone volume in prediction of hematologic toxicity in cervical cancer patients treated with chemoradiation (2016) (4)
- Targeting angiogenesis: Vascular endothelial growth factor and related signaling pathways (2015) (4)
- No evidence for BCL10 mutation in endometrial cancers with microsatellite instability (2001) (4)
- Postpartum sterilization: small incision, big complication. (2008) (4)
- A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. (2016) (4)
- Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer (2010) (4)
- CD 83 Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical Cancer (2007) (4)
- Joint ENGOT and GOG Foundation requirements for trials with industry partners. (2019) (4)
- Fertility preservation in ovarian cancer (2010) (4)
- 2771 BRCA1 and BRCA2 mutations in 1691 epithelial ovarian tumors identify subgroups with distinct molecular characteristics (2015) (4)
- A cost effective strategy of bevacizumab in treatment of primary ovarian cancer — A subset analysis of ICON 7 trial (2012) (4)
- Current research on the use of hormonal therapy in the treatment of advanced or recurrent endometrial cancer (2004) (4)
- An unusual case of uterine PEComa presenting with disseminated intravascular coagulation (2019) (4)
- Clinical Indications for Human Papillomavirus Vaccination (2008) (3)
- Clinical outcome of atypical uterine smooth muscle tumors. (2006) (3)
- Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right? (2017) (3)
- Detection and significance of parametrial micrometastases in early-stage cervical cancer. (2011) (3)
- Comparative effectiveness of upfront treatment strategies for advanced-stage ovarian cancer (2013) (3)
- A chemoresponse assay and survival in primary ovarian cancer (2008) (3)
- Evidence for a protein synthesis-dependent and -independent TNF alpha cytolytic mechanism. (1995) (3)
- Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. (2021) (3)
- Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. (2020) (3)
- A clinical and radiographic variant of Wernicke-Korsakoff syndrome in a nonalcoholic patient (2006) (3)
- Frequent HOXA 11 and THBS 2 Promoter Methylation , and a Methylator Phenotype in Endometrial Adenocarcinoma 1 (2003) (3)
- Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer (2018) (3)
- European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies. (2020) (3)
- Predicted immunogenicity of CDK12 biallelic loss-of-function tumors varies across cancer types. (2021) (3)
- Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. (2019) (2)
- Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer (2020) (2)
- Infiltrating adenomyosis of the cervix with features of a low-grade stromal sarcoma: a case report and a literature review. (2014) (2)
- The clinical-pathologic factors relevant to intraperitoneal chemotherapy in ovarian cancer: An analysis of two Gynecologic Oncology Group trials (2008) (2)
- Fertility sparing therapy for ovarian cancer has inherent risks and benefits (2005) (2)
- 8005 Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs Trabectedin (T) + PLD in the ET743-OVA-301 clinical trial (2009) (2)
- Comparison of the cytostatic and cytolytic activity of tumor necrosis factor-alpha and interleukin 1 alpha in human malignant cell lines. (1992) (2)
- ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (2022) (2)
- Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube (2007) (2)
- 1251 Opportunistic Salpingectomy at Time of Non-Gynecologic Laparoscopic Procedures Would Significantly Reduce Ovarian Cancer Mortality and Would Reduce Overall Healthcare Expenditures (2019) (2)
- The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. (2021) (2)
- A randomized, open-label study comparing trabectedin and pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone for the treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (ET743-OVC-3006) (2019) (2)
- Late-Breaking Abstract 3: The commercialization of robotic surgery: Unsubstantiated marketing of gynecologic surgery by hospitals (2012) (2)
- Biologic therapies and personalized medicine in gynecologic malignancies. (2012) (2)
- Immune-response markers and actual response to immune-oncology therapy in uterine serous carcinoma. (2021) (2)
- Determination of the activated form of the progesterone receptor (PR) in endometrial cancer (EC). (2013) (2)
- Cerclage during trachelectomy for early-stage cervical cancer (2016) (2)
- State of the science: Contemporary front-line treatment of advanced ovarian cancer. (2022) (2)
- Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. (2009) (2)
- Sentinel node detection in cervical cancer with 99mTc-phytate (2007) (2)
- Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). (2018) (2)
- Does maintaining adjuvant chemotherapy dose intensity have an impact on the outcome of treatment in ovarian cancer patients?: A Gynecologic Oncology Group study (2012) (2)
- Deviations from guideline-based therapy for febrile neutropenia in cancer patients. (2012) (2)
- Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial (2021) (2)
- Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. (2019) (2)
- Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO). (2013) (2)
- Upfront maintenance with anti-vascular versus PARP inhibitors in advanced ovarian cancer: A cost-effective analysis (2020) (2)
- Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy (2018) (2)
- Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma (2021) (2)
- Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial. (2021) (2)
- Comprehensive genomic profiling of mucinous ovarian carcinoma with comparisons to mucinous colorectal carcinoma (2019) (1)
- Effects of radiation on TNF alpha-mediated cytolysis of cell lines derived from cervical carcinomas. (1992) (1)
- The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value. (2021) (1)
- Surgical volume and its effect on morbidity and mortality for endometrial cancer (2011) (1)
- Early diagnosis and treatment challenges of endodermal sinus tumors: A case report (2020) (1)
- Hemolytic Uremic Syndrome Presenting After Treatment of Endodermal Sinus Tumor (2004) (1)
- Is there a "Low Risk" Patient Population in Advanced Epithelial Ovarian Cancer?: A Critical Analysis. (2022) (1)
- Exploratory analysis of nibrin in advanced ovarian cancer (AOC) patients treated in the phase III OVA-301 trial. (2013) (1)
- Opportunistic salpingectomy would significantly reduce ovarian cancer mortality and would reduce overall healthcare expenditures (2019) (1)
- Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). (2020) (1)
- The importance of information, motivation, and behavioral skills (IMB): Healthcare provider perspectives on improving adherence to cervical cancer screening among at-risk women (2021) (1)
- Too much skin in the game? A paradigm shift in our understanding of vulvar and vaginal melanomas as distinct tumor types compared with cutaneous melanomas (2021) (1)
- The role of tumor necrosis factor receptors in tumor necrosis factor-alpha-mediated cytolysis of ovarian cancer cell lines. (1996) (1)
- HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. (2021) (1)
- Practice changing cervical cancer clinical trials. (2022) (1)
- A phase III study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer. (2014) (1)
- A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer. (2018) (1)
- 8 – Invasive Cancer of the Vulva (2018) (1)
- Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. (2021) (1)
- Role of beta-catenin in regulating vascular endothelial growth factor A (VEGF-A) expression in endometrial cancer (2006) (1)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. (2016) (1)
- Patterns of Care in Locally Advanced Vulvar Carcinoma (2012) (1)
- Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers (2022) (1)
- The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. (2022) (1)
- Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer (2014) (1)
- Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy. (2022) (1)
- Comparison of incidence of hypersensitivity reactions of paclitaxel infusions with titrated versus non-titrated infusions (2021) (1)
- Independent radiologic review in ovarian cancer research (2019) (1)
- Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006) (2019) (1)
- Iconographies supplémentaires de l'article : Predictors of massive blood loss in women with placenta accreta (2011) (1)
- Obesity, physical inactivity and symptoms after ovarian cancer treatment: Results from an International internet-based survey (2015) (1)
- Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study (2016) (1)
- Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study (2015) (1)
- Enhancing the needle count in the haystack: serial ultrasonography for low-to-moderate risk adnexal masses. (2013) (1)
- In assessing surrogate clinical trial end points: drug safety is a requisite. (2015) (1)
- Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity. (2021) (1)
- Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field (2014) (1)
- What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer (2022) (1)
- Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). (2022) (1)
- An ex vivo chemoresponse assay predicts carboplatin-induced progression-free interval in ovarian cancer. (2004) (1)
- 830P Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC) (2020) (1)
- An independent oncology second opinion program: 2020 pilot project. (2020) (0)
- ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer (2022) (0)
- Feasibility of a platform trial in rare gynecologic cancers based on molecular analysis (2020) (0)
- A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer (2006) (0)
- Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy (2018) (0)
- Comparative effectiveness of radical hysterectomy in elderly women with cervical cancer (2014) (0)
- Safety and efficiency of multiple square sutures to avoid peripartum hysterectomy (2012) (0)
- Utilization and safety of Sodium Hyaluronate-Carboxymethylcellulose (HA-CMC) adhesion barrier in hysterectomy (2012) (0)
- Heterogeneity in chemoresponsiveness of ovarian cancer as demonstrated by an ex vivo chemo response assay. (2004) (0)
- ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326) (2022) (0)
- Cancer never stops: SARS-CoV-2 pandemic and the effect on research within GOG partners (2021) (0)
- In vitro chemoresponse assay results and population clinical response rates in women with ovarian cancer. (2012) (0)
- Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients. (2018) (0)
- FOXL2 mutation is prevalent in metastatic adult granulosa cell tumors and is associated with improved survival (2021) (0)
- Surveillance testing in women following a diagnosis of early-stage endometrial cancer (2014) (0)
- The lysis of cervical carcinoma cells is synergistically increased by the combination of tumor necrosis factor α (TNF) and radiation (1992) (0)
- Fast Facts: Ovarialkarzinom (2018) (0)
- The Effect of Surgeon and Hospital Volume on Outcomes and Cost for Laparoscopic Hysterectomy (2011) (0)
- Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8) (2022) (0)
- Industry Supported Symposium Luncheon III: PARP Inhibition in Ovarian Cancer: Integrating the Science, the Clinical Data, and the Patient Voice to Enhance Care (2017) (0)
- Exploring molecular profiles of uterine carcinosarcoma with alterations in the chromatin remodeling pathway. (2021) (0)
- Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167) (2022) (0)
- Lymphadenectomy Influences the Utilization of Adjuvant Radiation Therapy in Early-stage Endometrial Cancer (2011) (0)
- Clinical trials, adaptability and the COVID-19 pandemic (2020) (0)
- Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report. (2008) (0)
- Iconographies supplémentaires de l'article : A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy (2011) (0)
- 10 and Replication Errors in Endometrical Cancers Allelic Loss of Sequences from the Long Arm of Chromosome Updated (2006) (0)
- Thomas Herzog, MD: How Do I Treat a Patient with Stage IIIC Epithelial Ovarian Cancer? (2011) (0)
- Highlights in ovarian cancer from the American Society of Clinical Oncology annual meeting. (2020) (0)
- The use of cytoprotectants in the treatment of gynecological malignancies (2006) (0)
- Does radical trachelectomy influence uterine blood supply (2007) (0)
- Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]. (2022) (0)
- Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy: GYNECOLOGIC MALIGNANCY (2008) (0)
- Abstract A85: A comparison of patient outcomes in advanced ovarian cancer: Assay-informed vs. empirically treated (2013) (0)
- TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (2022) (0)
- Survival Outcome of Recurrent Early-Stage Ovarian Cancer Patients—What Factors are Important? (2007) (0)
- Transcriptomic immune profiling for cervical squamous cell carcinoma: Does HPV type matter? (170) (2022) (0)
- Utility of endometrial sampling in the detection of uterine sarcomas (2007) (0)
- 15 Randomized double-blind placebo controlled trial of frontline maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: efficacy assessment in BRCA1/2-wt patients (2020) (0)
- Fast Facts: Ovarian Cancer (2017) (0)
- 2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer (2022) (0)
- Ex vivo chemoresponse assay of ovarian cancers predicts clinical outcome (2004) (0)
- The Genomic Landscape of Vulvar Squamous Cell Carcinoma. (2023) (0)
- Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies (2007) (0)
- Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. (2023) (0)
- Current awareness and use of bevacizumab in advanced cervical cancer: A survey among US community oncologists (2017) (0)
- Rate of bowel herniation in patients undergoing robotic surgery (2013) (0)
- Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. (2022) (0)
- Highlights in ovarian cancer from the European Society for Medical Oncology Virtual Congress 2020: commentary. (2020) (0)
- P28 Investigating molecular profiles of subtypes of mucosal melanomas: is vulvovaginal melanoma a distinct entity? (2022) (0)
- Ex vivo chemoresponse assay of ovarian cancers predicts clinical outcome. (2004) (0)
- A prospective study evaluating the clinical relevance of a chemoresponse assay fortreatment of patients with persistent or recurrent ovarian cancer (2013) (0)
- REMOVED: Cervical Squamous Cell Carcinoma and Adenocarcinoma: Etiology and Prevention (2009) (0)
- Association of radical cytoreductive surgery and perioperative complications with delay or omission of chemotherapy in ovarian cancer (2012) (0)
- Role of PI3-kinase signalling in uterine carcinosarcoma (2012) (0)
- Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma. (2021) (0)
- NCOLOGY mplification of the chromosome 3 q 26 region shows igh negative predictive value for nonmalignant ransformation of LSIL cytologic finding (2010) (0)
- Comprehensive molecular profiles of low-grade serous ovarian carcinoma (2019) (0)
- Maintenance therapy with PARP inhibition in ovarian cancer. (2022) (0)
- Abstract 4253: Pan-cancer analysis of XPO1 R749Q mutations across 217,570 patients reveals association with high tumor mutational burden and therapy resistance (2023) (0)
- 2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68) (2022) (0)
- The challenge of paying for our targeted future (2005) (0)
- Opportunistic Salpingectomy at Time of Nongynecologic Elective Procedures Could Reduce Ovarian Cancer–Related Costs and Mortality (2021) (0)
- A pretreatment mass spectrometry-based serum proteomic test is able to stratify patients with ovarian cancer receiving adjuvant chemotherapy according to overall and progression-free survival and identify patients likely to exhibit chemoresistance (2017) (0)
- 290Stage IC ovarian cancer: Tumor rupture versus ovarian surface involvement (2011) (0)
- Kevin Analysis A Cost-Effectiveness − − Bevacizumab in Treatment of High-Risk Ovarian Cancer (2014) (0)
- IGCS 20 _ 1454 417 KRAS MUTANT UTERINE CARCINOMAS (2020) (0)
- Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors. (2023) (0)
- Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer (2014) (0)
- Heterogeneity in chemoresponsiveness of ovarian cancer as demonstrated by an ex vivo chemo response assay (2004) (0)
- TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66) (2022) (0)
- Treatment of Endometrial Cancers(Oncology,International Seminar) (2014) (0)
- 844P KRAS mutant epithelial ovarian carcinomas (EOC) represent distinct genomic genotypes (2020) (0)
- Vulvovaginal melanoma or vulvar and vaginal melanoma: Can these tumors be considered the same? (009) (2022) (0)
- Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma. (2021) (0)
- 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246) (2022) (0)
- Minimal Vaginal Displacement With Use of a Rectal Balloon During Pelvic IMRT for Gynecologic Malignancies (2013) (0)
- Room 501 A-C, Los Angeles Convention Center Epidemiology 11 Inflammation, Immunity, and Novel Pathways (2007) (0)
- 3)Treatment of Endometrial Cancer(State-of-the-art:Gynecologic Oncology,International Seminar 2) (2011) (0)
- NON-ORAL POSTER 35: Gastrointestinal Recovery After Simple Hysterectomy: Analysis of Placebo Data From a Randomized, Controlled Trial (2006) (0)
- Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. (2020) (0)
- The prognostic significance of pre-operative vs. prechemotherapy CA-125 in high-risk early-stage epithelial ovarian cancer: A gynecologic oncology group study (2010) (0)
- ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. (2022) (0)
- Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer (2014) (0)
- A state by state analysis of BRCA1 and BRCA2 testing in patients with ovarian cancer (2015) (0)
- NON-ORAL POSTER 41: A Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial of The Safety of Alvimopan (ALV) in Patients (PTS) Undergoing Total Abdominal Hysterectomy (TAH) (2005) (0)
- Postpartum colposcopy – Is it necessary? (2019) (0)
- A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer (2014) (0)
- Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? (2018) (0)
- Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer (2022) (0)
- A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types. (2021) (0)
- Pelvic Masses in Obese Women (2003) (0)
- A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004). (2021) (0)
- The pattern of CA-125 normalization during chemotherapy predicts for recurrence and survival in patients with high-risk early-stage ovarian cancer: A gynecologic oncology group study (2010) (0)
- Identification of master regulators of cisplatin resistance in ovarian cancer (2013) (0)
- Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling (2023) (0)
- A case of a unique presentation of a primary vaginal endometrioid adenocarcinoma arising in the setting of a recurrent peritoneal inclusion cyst fistulized to the vagina (2020) (0)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensit (2021) (0)
- Investigating molecular profiles of subtypes of mucosal melanomas: Is vulvovaginal melanoma a distinct entity? (263) (2022) (0)
- Supporting gynecologic cancer research: the last 20 years and beyond. (2011) (0)
- Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target (2014) (0)
- Efficacy of and Prognostic Factors in Cervical Loop Excision (1997) (0)
- Atlas of Colposcopy (2008) (0)
- Molecular analysis of endometrioid and non-endometrioid uterine cancer and response to treatment (246) (2022) (0)
- How do I treat a patient with Stage IIIC epithelial ovarian cancer (2011) (0)
- Fertility options in women with gynecologic malignancies (2005) (0)
- Resource utilization for cancer patients at the end of life : How much is too/much? (2006) (0)
- Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients (2002) (0)
- A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer. (2010) (0)
- Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study (2016) (0)
- Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. (2019) (0)
- Effect of surgeon and hospital volumes on outcome for women undergoing radical hysterectomy for cervical cancer (2011) (0)
- Correlation of CCNE1 copy number levels with molecular profiles and outcomes for high grade serous ovarian and endometrial cancer (121) (2022) (0)
- 594P The heterogeneic molecular landscape of ovarian cancer metastases (OCM) (2022) (0)
- Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study (2022) (0)
- Assessment of the cytotoxic potential of aminopterin in gynecologic malignant cell lines (1999) (0)
- The unique natural history of mucinous tumors of the ovary (2011) (0)
- Highlights in ovarian cancer from the 2017 Society of Gynecologic Oncology annual meeting on women's cancer: Commentary. (2017) (0)
- Molecular variations in uterine carcinosarcomas: Are there therapeutic opportunities? (2018) (0)
- Transcriptomic immune profiling: a precision path forward for immunotherapy in patients with cervical cancer? (2021) (0)
- Lower extremity lymphedema (2002) (0)
- How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO). (2012) (0)
- Comparative effectiveness of minimally invasive radical hysterectomy for cervical cancer (2012) (0)
- 566 ENTPD1 as predictive marker of treatment response to gemogenovatucel-T (Vigil) in newly diagnosed ovarian cancer (2022) (0)
- Editorial: Women's oncology in the twenty-first century (2003) (0)
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. (2023) (0)
- Is there a microinvasive cervical adenocarcinoma (2011) (0)
- Single cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer (2023) (0)
- Increased sensitivity to adriamycin and reversal of resistance to cisplatin by cyclosporin a or emetine in ovarian carcinoma cell lines (1992) (0)
- Abstract 169: Temporal trends, predictors, and outcome of chemotherapy in elderly women with advanced stage endometrial cancer. (2013) (0)
- The Genomic Landscape of Vulvovaginal Squamous Cell Carcinoma (048) (2022) (0)
- Best Ovarian Cancer Research of 2011: Yearning for Personalized Medicine (2012) (0)
- Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171) (2022) (0)
- NOTCH2 as a tumor suppressor in epithelial ovarian cancer (2012) (0)
- Iconographies supplémentaires de l'article : Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer (2011) (0)
- Patterns of TP53 and KRAS2 mutations in a large series of endometrial cancers characterized for DNA mismatch repair (1998) (0)
- Delayed recurrences and survival after relapse in patients initially treated with intraperitoneal chemotherapy for advanced ovarian cancer: A Gynecologic Oncology Group study. (2015) (0)
- Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy (2017) (0)
- TP026/#1435 Phase 3 study of efficacy & safety of Olvi-Vec and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (ONPRIME; GOG-3076) [NCT05281471] (2022) (0)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer (2021) (0)
- Comprar Atlas of Colposcopy | F. Stewart Massad | 9781842142677 | Informa Healthcare (2008) (0)
- Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers. (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas J. Herzog?
Thomas J. Herzog is affiliated with the following schools:
